Mustang Bio, Inc.

53 articles with Mustang Bio, Inc.

• Mustang Bio Announces Positive Opinion from the European Medicines Agency on Orphan Drug Designation for Its Lentiviral Gene Therapy for the Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”)

  11/24/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the European Commission (“EC”) issued a positive opinion on its application for Orphan Drug Designation for Mustang’s lentiviral gene therapy for the treatment of X-linke

• Mustang Bio and Minaris Regenerative Medicine Sign Technology Transfer and GMP Manufacturing Agreement for MB-107 Lentiviral Gene Therapy for X-Linked Severe Combined Immunodeficiency

  11/23/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing service provider for the cell and gene therapy industry, today announc

• Mustang Bio Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

  11/6/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2020. “Mustang had an eventful third quarter on the regulatory front, as the U.S.

• Mustang Bio Announces MB-106 Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting

  11/4/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”), have been s

• Mustang Bio Announces Initial Phase 1 Data on MB-105 for Patients with PSCA-positive Castration Resistant Prostate CancerData presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat

  10/26/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that one patient‘s experience on the Phase 1 trial of MB-105,

• Mustang Bio to Participate in Chardan’s Virtual 4th Annual Genetic Medicines Conference 2020

  10/1/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at Chardan’s Virtual 4 th Annual Genetic Medicines Conference 2020 on M

• Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)

  10/1/2020

  Safety and efficacy to be evaluated in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia and high-risk myelodysplastic syndrome

• Mustang Bio to Participate in Three September 2020 Virtual Investor Conferences

  9/10/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in September 2020.

• Mustang Bio Announces Orphan Drug Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

  9/2/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to MB-107, Mustang’s lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (“XSCID”), also known as bubble boy disease

• Mustang Bio Announces Rare Pediatric Disease Designation for MB-207 for the Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

  8/31/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation to MB-207,

• Mustang Bio to Present at the Virtual Fortress Biotech Corporate Access Summit

  8/17/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in the two-day Fortress Biotech (“Fortress”) Virtual Summit taking place on Tuesday, August

• Mustang Bio Announces Rare Pediatric Disease Designation for MB-107 for the Treatment of X-linked Severe Combined Immunodeficiency

  8/17/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Rare Pediatric Disease Designation to MB-107,  Mustang’s lentiviral gene therapy for the treatment of X-linked s

• Mustang Bio Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

  8/10/2020

  Mustang Bio, Inc. announced financial results and recent corporate highlights for the second quarter ended June 30, 2020.

• Mustang Bio Announces Pricing of Public Offering of Common Stock

  6/11/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced the pricing of its previously announced underwritten public offering. Mustang is offering 10,769,231 shares of its common stock, par value $0.0001 per share, at a price to the

• Mustang Bio Announces Proposed Public Offering of Common Stock

  6/10/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering

• Mustang Bio to Host Virtual Annual Meeting of Stockholders

  6/4/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”) virtually due to public health concerns resulting from the coronavirus (“COVID-19”) outb

• Mustang Bio Announces Presentations at 23rd Annual Meeting of the American Society of Gene & Cell Therapy

  5/12/2020

  Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced two poster presentations at the virtual 23rd Annual Meeting of the American Society of Gene & Cell Therapy (“ASGCT”), being held May 12-15, 2020. Manuel Litchman, M.D., P

• Mustang Bio Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

  5/11/2020

  Mustang Bio, Inc. announced financial results and recent corporate highlights for the first quarter ended March 31, 2020.

• Mustang Bio Reports Full-Year 2019 Financial Results and Recent Corporate Highlights

  3/16/2020

  Mustang Bio, Inc. today announced financial results and recent corporate highlights for the full year ended December 31, 2019. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “We are

• 

  Clinical Catch-Up: February 17-21

  2/24/2020

  Mid-February had a solid number of clinical trial announcements. Here’s a look.